Moneycontrol
    Moneycontrol PRO

    Jump to

    • Generic drugs Vs brand: Here's how experts are looking at it

    • Prescribing generic medicines may commoditise entire pharma industry: Experts

    • Demerger of pharma, financial srvs biz to take 2 years: Piramal

    • Aim is to prevent rampant use of antibiotics: P Lilladher

    • More clarity needed on non-compete clause: Medybiz

    • Pharma sector moots market-based pricing: Pfizer

      In an interview to CNBC-TV18, Kewal Handa, managing director of Pfizer and Vikas Dandekar, India Bureau Chief of PharmAsia News.Com discuss the issue of drug pricing.

    • No short-term revenue impact from split with Pfizer: Biocon

      In an exclusive interview to CNBC-TV18, Kiran Mazumdar Shaw of Biocon says that the breakup with Pfizer will not have any short-term impact on revenues for either company, but will reflect in the fourth quarter financials.

    • Biocon-Pfizer insulin deal might collapse soon: PharmAsia

      The deal between Biocon and Pfizer to market a range of insulin products may be in crisis. Vikas Dandekar, the India Bureau Chief of PharmAsia News who broke this story tells CNBC-TV18 that while sources are saying talks are on to salvage the deal, it is most likely to be called off.

    • Govt needs to relook at draft pharma pricing policy: Pfizer

      Speaking to CNBC-TV18, Kewal Handa, managing director of Pfizer said, the draft NPPP has a few positives but the government needs to re-look at it altogether.

    • CCI's role key in pharma FDI; FIPB not best option: Pfizer

      The Arun Maira committee report on pharma FDI was accepted by the government which said the CCI should be entrusted with the task of scrutinising pharma FDI in brownfield projects. Kewal Handa, Country Manager at Pfizer India tells CNBC-TV18 feels it is just going back to the old regime of FIPB.

    • Strides, Pfizer to deal post US FDA nod on Oncology unit

      Strides Arcolab received a nod by the US FDA for an Oncology unit in Bengaluru. Arun Kumar, group CEO and vice chairman of Strides Arcolab, in an exclusive interview with CNBC-TV18 shares that the company expects approvals on approximately USD 4-5 billon product filings in the next few weeks.

    • Blocking Ranbaxy's launch of cholesterol drug, where is the logic?

      The US Foods and Drugs Administration (USFDA) will be sued by the US pharmaceutical company Mylan Inc, for an injunction on the launch of Ranbaxy’s cholesterol treatment drug Aricept, which is a generic version of Pfizer’s Lipitor.

    • Business to grow Rs 1000cr in FY11: Stride Arcolab

      Stride Arcolab announced it Q3 results for FY11. The company reported a consolidated net profit of Rs 122.4 crore for the year ended 2010 as against Rs 109.7 crore in previous year.

    • Clinigene & Syngene may list in a year's time: Biocon

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347